These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 28849584)

  • 21. Obatoclax as a perpetrator in drug-drug interactions and its efficacy in multidrug resistance cell lines.
    Theile D; Allendorf D; Köhler BC; Jassowicz A; Weiss J
    J Pharm Pharmacol; 2015 Nov; 67(11):1575-84. PubMed ID: 26255619
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhanced glucose absorption in the rat small intestine following repeated doses of 5-fluorouracil.
    Tomimatsu T; Horie T
    Chem Biol Interact; 2005 Aug; 155(3):129-39. PubMed ID: 15996645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Study on the relationship between breast cancer resistance protein expression and 5-fluorouracil resistance].
    Yuan JH; Cheng JQ; Ke YB; Ji NN; Zhou JM; Zhou L; Huang HY; Yang LQ; Liu JJ; Xu XY; Zhuang ZX
    Zhonghua Yu Fang Yi Xue Za Zhi; 2008 Jul; 42(7):506-10. PubMed ID: 19035187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deletion of Abcg2 has differential effects on excretion and pharmacokinetics of probe substrates in rats.
    Huang L; Be X; Tchaparian EH; Colletti AE; Roberts J; Langley M; Ling Y; Wong BK; Jin L
    J Pharmacol Exp Ther; 2012 Nov; 343(2):316-24. PubMed ID: 22869929
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suppression of drug-metabolizing enzymes and efflux transporters in the intestine of endotoxin-treated rats.
    Kalitsky-Szirtes J; Shayeganpour A; Brocks DR; Piquette-Miller M
    Drug Metab Dispos; 2004 Jan; 32(1):20-7. PubMed ID: 14709616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of
    Kawami M; Yamada Y; Toshimori F; Issarachot O; Junyaprasert VB; Yumoto R; Takano M
    Pharmazie; 2017 Feb; 72(2):123-127. PubMed ID: 29441866
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo.
    Ceckova M; Libra A; Pavek P; Nachtigal P; Brabec M; Fuchs R; Staud F
    Clin Exp Pharmacol Physiol; 2006; 33(1-2):58-65. PubMed ID: 16445700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
    Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of rat intestinal P-glycoprotein by spironolactone and its effect on absorption of orally administered digoxin.
    Ghanem CI; Gómez PC; Arana MC; Perassolo M; Delli Carpini G; Luquita MG; Veggi LM; Catania VA; Bengochea LA; Mottino AD
    J Pharmacol Exp Ther; 2006 Sep; 318(3):1146-52. PubMed ID: 16740618
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In Vitro-In Vivo Extrapolation Scaling Factors for Intestinal P-glycoprotein and Breast Cancer Resistance Protein: Part II. The Impact of Cross-Laboratory Variations of Intestinal Transporter Relative Expression Factors on Predicted Drug Disposition.
    Harwood MD; Achour B; Neuhoff S; Russell MR; Carlson G; Warhurst G; Rostami-Hodjegan A
    Drug Metab Dispos; 2016 Mar; 44(3):476-80. PubMed ID: 26842595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Breast cancer resistance protein expression and 5-fluorouracil resistance.
    Yuan JH; Cheng JQ; Jiang LY; Ji WD; Guo LF; Liu JJ; Xu XY; He JS; Wang XM; Zhuang ZX
    Biomed Environ Sci; 2008 Aug; 21(4):290-5. PubMed ID: 18837291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions.
    Reyner EL; Sevidal S; West MA; Clouser-Roche A; Freiwald S; Fenner K; Ullah M; Lee CA; Smith BJ
    Drug Metab Dispos; 2013 Aug; 41(8):1575-83. PubMed ID: 23729661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Subchronic Intravenous Morphine Infusion and Naloxone-Precipitated Morphine Withdrawal on P-gp and Bcrp at the Rat Blood-Brain Barrier.
    Chaves C; Gómez-Zepeda D; Auvity S; Menet MC; Crété D; Labat L; Remião F; Cisternino S; Declèves X
    J Pharm Sci; 2016 Jan; 105(1):350-8. PubMed ID: 26554626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
    Kodaira H; Kusuhara H; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2010 Jun; 333(3):788-96. PubMed ID: 20304939
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2).
    Shen H; Lee FY; Gan J
    J Pharmacol Exp Ther; 2011 May; 337(2):423-32. PubMed ID: 21262849
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of ATP-binding cassette membrane transporters in rodent and human sertoli cells: relevance to the permeability of antiretroviral therapy at the blood-testis barrier.
    Robillard KR; Hoque T; Bendayan R
    J Pharmacol Exp Ther; 2012 Jan; 340(1):96-108. PubMed ID: 21990609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ABCB1 and ABCG2 proteins, their functional activity and gene expression in concert with drug sensitivity of leukemia cells.
    Svirnovski AI; Shman TV; Serhiyenka TF; Savitski VP; Smolnikova VV; Fedasenka UU
    Hematology; 2009 Aug; 14(4):204-12. PubMed ID: 19635183
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of oxygen on multidrug resistance in term human placenta.
    Javam M; Audette MC; Iqbal M; Bloise E; Gibb W; Matthews SG
    Placenta; 2014 May; 35(5):324-30. PubMed ID: 24685282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of transporters in the disposition of the selective phosphodiesterase-4 inhibitor (+)-2-[4-({[2-(benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid in rat and human.
    Kalgutkar AS; Feng B; Nguyen HT; Frederick KS; Campbell SD; Hatch HL; Bi YA; Kazolias DC; Davidson RE; Mireles RJ; Duignan DB; Choo EF; Zhao SX
    Drug Metab Dispos; 2007 Nov; 35(11):2111-8. PubMed ID: 17686907
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2.
    Mease K; Sane R; Podila L; Taub ME
    J Pharm Sci; 2012 May; 101(5):1888-97. PubMed ID: 22359351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.